Drawing for GINCOSAN

USPTO serial 79060908

GINCOSAN

Reviewed by CopyMark Law Group

Reg. 3722530Status 404
Filing date
Status date
Registration date
Dec 8, 2009
Examiner
SERVANCE, RENEE L
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with GINCOSAN?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical and dietetic products for healthy and sick persons for medical use, namely, dietetic foods adapted for medical use and pharmaceutical preparations for treatment of deficient mental capacities, lack of concentration and attention, defective memory in case of arteriosclerotic symptoms such as dizziness, changing mood, difficulties of adaptation and contactSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Nov 5, 2023DENCNOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED—
Nov 5, 2023DETHDEATH OF INTERNATIONAL REGISTRATION—
Jul 16, 2020ADCHCHANGE OF NAME/ADDRESS REC'D FROM IB—
Jan 18, 2018NREPNEW REPRESENTATIVE AT IB RECEIVED—
May 19, 2017INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Apr 8, 2017INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Apr 8, 2017INPCINVALIDATION PROCESSED—
Mar 15, 2017INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jan 5, 2017NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jul 15, 2016C71TCANCELLED SECTION 71—
Mar 12, 2015NREPNEW REPRESENTATIVE AT IB RECEIVED—
Jun 19, 2014NREPNEW REPRESENTATIVE AT IB RECEIVED—
Oct 4, 2013NREPNEW REPRESENTATIVE AT IB RECEIVED—
Apr 26, 2013RNWLINTERNATIONAL REGISTRATION RENEWED—
Apr 14, 2013FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Mar 24, 2010FICSFINAL DISPOSITION NOTICE SENT TO IB—
Mar 24, 2010FIMPFINAL DISPOSITION PROCESSED—
Mar 8, 2010FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Feb 25, 2010CHLDCHANGE OF OWNER RECEIVED FROM IB—
Dec 8, 2009R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Sep 22, 2009PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Sep 2, 2009NPUBNOTICE OF PUBLICATION—
Aug 17, 2009PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Aug 17, 2009CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Aug 5, 2009ACECAMENDMENT FROM APPLICANT ENTERED—
Aug 5, 2009CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Aug 5, 2009ALIEASSIGNED TO LIE—
Jul 20, 2009MAILPAPER RECEIVED—
Feb 13, 2009RFNTREFUSAL PROCESSED BY IB—
Dec 30, 2008RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Dec 30, 2008RFRRREFUSAL PROCESSED BY MPU—
Dec 28, 2008RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Dec 27, 2008CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 27, 2008DOCKASSIGNED TO EXAMINER—
Nov 25, 2008MAFRAPPLICATION FILING RECEIPT MAILED—
Nov 21, 2008NWAPNEW APPLICATION ENTERED—
Nov 20, 2008SDRCSN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB—

Frequently asked questions

Related guidance